retatrutide clinical trial results weight loss 2024 2025 press release Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide: FDA approval time, trial

Excess body fat in obese and normal-weight subjects

Although a causal association with acute pancreatitis remains debated, observational studies suggest a higher incidence compared with placebo (Nieto et al., 2025

Minor forms of thalassemia are generally asymptomatic and do not require therapeutic intervention (Merck 2008b)

McHugh told John in the coming months, employer customers of BCBS will choose whether or not they'd like to include GLP-1 coverage in their plans

Based on current clinical trial data and the medications mechanism of action, retatrutide may be particularly beneficial for: Individuals with significant obesity (BMI 30+) who need substantial weight loss People with type 2 diabetes seeking both glycemic control and weight reduction Patients with non-alcoholic fatty liver disease the liver fat reduction data is among the most impressive for any medication Those who have plateaued on semaglutide or tirzepatide the additional glucagon pathway may overcome metabolic adaptation Individuals with insulin resistance or metabolic syndrome the comprehensive metabolic effects address multiple aspects of metabolic dysfunction Retatrutide may not be appropriate for: Individuals with a history of medullary thyroid carcinoma or MEN2 syndrome Patients with severe gastrointestinal disorders Pregnant or breastfeeding women Those with a history of pancreatitis Individuals with certain endocrine or thyroid conditions A comprehensive medical evaluation including laboratory testing is essential before starting any weight loss medication